$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Medical Research

Early Stents Fail To Extend Life In Stable Disease

ISCHEMIA-EXTEND followed more than 5,000 patients for up to 13 years: 26 percent died after an early invasive strategy, 27 percent after medicines first. The procedures relieve chest pain — the trial is careful about that — but in stable coronary disease, starting with pills doesn't cost years.

TML Health DeskNov 11, 1:31 PM ET · 2 min read Updated Nov 15, 10:38 AM ET

Edited and fact-checked by Stephen Sprague

A coronary stenting procedure (archive) in a catheterization lab. ISCHEMIA-EXTEND followed more than 5,000 patients for up to 13 years and found 26 percent died after an early invasive strategy, against 27 percent after medicines first. Photo: WakeMed Heart & Vascular / CC BY 4.0, via Wikimedia Commons.
Summary

In a follow-up of more than 5,000 heart patients over up to 13 years, death rates were 26% with early stents and surgery versus 27% with medication-first care.

Tap a passage. React to the part that matters.

After nearly a decade, patients who got early stents were no more likely to be alive than patients who started with pills.

ISCHEMIA-EXTEND followed more than 5,000 people with stable coronary disease for up to 13 years. Death rates were 26 percent with an early invasive strategy and 27 percent with medicines first — a one-point gap after 1,071 deaths, published in JAMA November 7.

The trial underneath, ISCHEMIA, randomized patients with stable coronary artery disease and abnormal stress tests to two strategies: go in early — angiography, stents or bypass surgery, plus medication — or start with medication and lifestyle change, reserving procedures for when medical therapy failed. The original trial found no survival advantage to going in early. EXTEND, led by NYU Langone Health researchers and presented November 7 at the American Heart Association's Scientific Sessions, asked whether time reversed that answer. It didn't — and the follow-up is unusually complete, with vital status confirmed for 96 percent of participants as far as 13 years out.

Read the headline numbers the way this desk insists: in absolute terms, 26 versus 27 percent is roughly one death's difference per hundred patients across a decade — a gap the trial reads as a tie, not a trend. What the invasive strategy did do, in the original trial, is relieve chest pain and improve quality of life for patients who had angina. And the finding has a fence around it: heart attacks and unstable disease are a different universe, where procedures save lives on a timer. This result governs one specific, very common moment — a stable patient, an abnormal stress test, no emergency — and it says the clock doesn't punish starting with medicine.

The caveats are real. EXTEND didn't track nonfatal heart attacks, repeat procedures or quality of life beyond the initial trial period, so the symptom story after the first several years is untold here. But the question patients actually ask in that office — will going in now make me live longer — now has the longest and most complete answer cardiology has produced: no. Relief is a reason. Years aren't.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.